Ficlatuzumab
As of the edition of 20 October 2026, Ficlatuzumab is an antibody: in active development; acts on HGF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 14, 5 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Lungs and airways; Ear, nose and throat; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HGF | Hepatocyte growth factor | P14210 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 7 | 4 | 0 | 3 |
| Phase 2 | 4 | 2 | 0 | 2 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 14 |